816284--2/18/2010--CELGENE_CORP

related topics

{product, liability, claim}

{financial, litigation, operation}

{product, candidate, development}

{operation, international, foreign}

{system, service, information}

{personnel, key, retain}

{provision, law, control}

{acquisition, growth, future}

{stock, price, operating}

{control, financial, internal}

{customer, product, revenue}

{tax, income, asset}

{condition, economic, financial}

{competitive, industry, competition}

{cost, regulation, environmental}

We remain dependent on the continued commercial success of our primary products REVLIMID , THALOMID and VIDAZA and a significant decline in demand for or use of these products or our other commercially available products could materially and adversely affect our operating results. Sales of our products will be significantly reduced if access to and reimbursement for our products by governmental and other third party payors is reduced or terminated. If we do not gain or maintain regulatory approval of our products we will be unable to sell our current products and products in development. Our products may face competition from lower cost generic or follow-on products and providers of these products may be able to sell them at a substantially lower cost than us. If we are not able to effectively compete our business will be adversely affected. We may be required to modify our business practices, pay fines and significant expenses or experience losses due to governmental investigations or other litigation. The development of new biopharmaceutical products involves a lengthy and complex process, and we may be unable to commercialize any of the products we are currently developing. Manufacturing and distribution risks including a disruption at certain of our manufacturing sites would significantly interrupt our production capabilities, which could result in significant product delays and adversely affect our results. The consolidation of drug wholesalers and other wholesaler actions could increase competitive and pricing pressures on pharmaceutical manufacturers, including us. Risks from the improper conduct of employees, agents or contractors or collaborators could adversely affect our business or reputation. We may face significant challenges in effectively integrating entities and businesses that we acquire and we may not realize the benefits that we anticipate from any such acquisition. Our failure to attract and retain key managerial, technical, scientific, selling and marketing personnel could adversely affect our business. We could be subject to significant liability as a result of risks associated with using hazardous materials in our business. Changes in our effective income tax rate could adversely affect our results of operations. Currency fluctuations and changes in exchange rates could increase our costs and may cause our profitability to decline. We may experience an adverse market reaction if we are unable to meet our financial reporting obligations. The decline of global economic conditions could adversely affect our results of operations. The price of our common stock may fluctuate significantly and you may lose some or all of your investment in us. A breakdown or breach of our information technology systems could subject us to liability or interrupt the operation of our business. We have certain charter and by-law provisions that may deter a third-party from acquiring us and may impede the stockholders ability to remove and replace our management or board of directors.

Full 10-K form ▸

816284--2/18/2010--CELGENE_CORP_/DE/